Response to Official Action mailed July 6, 2001 U.S. Patent Application No. 10/590,073 Nicolau *et al.*

AMENDMENT

In the Claims

This listing of claims will replace all prior versions and listings of claims.

1-18. (Cancelled)

- 19. (Currently Amended) A method for restoring memory and curiosity awakening enhancing antigenicity in a patient suffering from Alzheimer's disease comprising administering to a patient in need thereof a supramolecular antigenic construct comprising reconstituted in a liposome, wherein the supramolecular antigenic construct emprises an antigenic peptide modified with hydrophobic moieties and reconstituted in a liposome, wherein the antigenic peptide is consisting of the amino acid sequence of β-amyloid or an active fragment thereof, wherein the antigenic peptide or active fragment thereof is modified with hydrophobic moieties to enhance antigenicity, and increased levels of memory restoration and curiosity awakening as compared to prior to administration.
- 20. (Currently Amended) The method of claim 19, wherein the <u>hydrophobic moieties are</u> antigenic peptide or active fragment thereof is modified by pegylation, palmitic acid, poly-amino acids, poly-glycine, poly-histidine, poly-saccharides, polygalacturonic acid, polylactic acid, polyglycolide, chitin, chitosan, synthetic polymers, polyamides, polyurethanes, polyesters, co-polymers or poly(methacrylic acid) and N-(2-hydroxy)propyl methacrylamide.

Response to Official Action mailed July 6, 2001 U.S. Patent Application No. 10/590,073 Nicolau *et al.*

- 21. (Canceled)
- 22. (Canceled)
- 23. (Currently Amended) The method of claim 19, wherein the supramolecular antigenic construct is reconstituted in liposomes consist consisting of phospholipids and cholesterol.
- 24. (Canceled)
- 25. (Currently Amended) The method of claim 19, wherein the <u>antigenic amyloid peptide is</u> comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
- 26. (Currently Amended) The method of claim 19, wherein the supramolecular antigenic construct further comprises comprising a pharmaceutical carrier.
- 27. (Canceled)
- 28. (Previously Presented) The method of claim 19, wherein the patient is an animal or human.
- 29. (Currently Amended) The method of claim 19, wherein a portion of the β-amyloid fragment consist of a is a fragment comprising the GXXXG motif.
- 30. (Currently Amended) The method of claim 19, wherein a portion of the β-amyloid fragment consist of a is a fragment comprising the GXXXGXXXGG motif.

Response to Official Action mailed July 6, 2001 U.S. Patent Application No. 10/590,073 Nicolau *et al.*

- 31. (New) The method of claim 20, wherein said hydrophobic moieties are fatty acids, triglycerides or phospholipids.
- 32. (New) The method of claim 31, wherein said hydrophobic moieties have a carbon backbone of at least 14 and up to 24 carbon atoms.